INTRODUCTION {#sec1-1}
============

Nowadays, bioactive agents from natural sources are discovered and screened for their therapeutic efficacy. Natural products are known to account for 30% of international drug sales. Although most of the medicines are derived from terrestrial plants and animals, ecologists estimate the number of the species in the marine environment to be 0.5-10 million.\[[@ref1]\] Most of these are still on the verge to be discovered. Well, that may be the reason behind therapeutic efficacy of natural products being predominantly achieved in antibiotic therapies, oncology, and immune regulation. Natural products are generally not related to the biological environment of the producing organism, henceforth it is less likely to identify potent natural products against molecular targets. Furthermore, higher hit rates are generally obtained for natural product libraries in high throughput screening campaigns (HTS) compared to medchem or combichem libraries. Certainly, natural products are a valuable source of unsurpassed structural diversity and functional density to identify screening hits. After a long period, natural products drug discovery has again gained attention. Also, World Health Organization (WHO) has been promoting traditional medicines as a source of less expensive, comprehensive medical care, especially in developing countries. However, despite the promise of these alternative drug discovery methods, there is still a shortage of lead compounds progressing into the clinical trials. This is specially the case in therapeutic areas such as oncology, immunosuppression, and metabolic diseases where natural products have played a central role in drug discovery.

BIOSYNTHETIC ASPECTS {#sec1-2}
====================

The biosynthesis of taraxerol (VI) is same up to formation of squalene to (3S)-2, 3-epoxy-2, 3-dihydrosqualene biosynthesis as in the biosynthesis scheme of triterpenes by enzymes oxidosqualene cyclases. After this, (3S)-2, 3-epoxy-2, 3-dihydrosqualene gets converted to olean-13-yl cation, which is further converted to taraxerol by the action of enzyme taraxerol synthase Systematic name: (3*S*)-2, 3-epoxy-2, 3-dihydrosqualene mutase (cyclizing, taraxerol-forming). The enzyme gives taraxerol, β-amyrin, and lupeol in the ratio 70:17:13. Also the olean-13-yl cation undergoes a series of rearrangement reactions to give isomultifluorenol, Ψ taraxasterol, and taraxasterol (VII) [Figure 1](#F1){ref-type="fig"}.\[[@ref2]\]

![Biosynthetic pathways followed by Taraxasterol and Taraxasterol: Sqaualene act as a precursor molecule lead to formation of (3S)-2, 3-epoxy-2, 3-dihydrosqualene (I), dammarenyl cation (II), baccharenyl cation (III), lupanyl cation (IV), and olean-19-yl-cation (V), olean-19-ylcation further forms taraxerol (VI), taraxasterol (VII), iso-mumultiflurenol (VIII), glutinol (IX), and friedelin (X)](PRev-9-19-g001){#F1}

Chemistry {#sec2-1}
---------

The CAS name of Taraxerol, [Figure 2a](#F2){ref-type="fig"} is (3b)- D-Friedoolean-14-en-3-ol. Its additional names include isoolean-14-en-3b-ol, skimmiol, alnulin, tiliadin. Its molecular formula is C~30~H~50~O and molecular weight is 426.72. Its melting point is 282-285°C. Its structure was given by Beaton *et al.*\[[@ref3]\] The CAS name of Taraxasterol, [Figure 2b](#F2){ref-type="fig"} is (3b, 18a, 19a)-Urs-20 (30)-en-3-ol. Its molecular formula is C~30~H~50~O and molecular weight is 426.72 same as Taraxerol. Its structure and configuration was reported by Ames *et al.*\[[@ref4]\] The insecticidally inactive substance pyrethrol from pyrethrum flowers has been identified as taraxasterol.\[[@ref5]\] Both Taraxerol and Taraxasterol were investigated by high-performance liquid chromatography (HPLC) using methanol containing 0.1% phosphoric acid.\[[@ref6]\] A simple and precise high-performance thin layer chromatography (HPTLC) method has been developed for estimation of Taraxerol with hexane and ethyl acetate (80:20 v/v), using visualizing agent anisaldehyde sulphuric acid, and scanning of plate was done at 420 nm. The system was found to give compact spots for Taraxerol (R~f~ 0.53).\[[@ref7]\]

![(a) Structure of Taraxerol (3β)-D-Friedoolean-14-en- 3ol) (b) Structure of Taraxasterol (3β, 18α, 19α)-Urs- 20(30)-en-3-ol)](PRev-9-19-g002){#F2}

Pharmacological actions {#sec2-2}
-----------------------

Taraxerol and taraxasterol are important compounds that possess anti-tumor actions.\[[@ref8]\] Taraxerol showed significant anti-inflammatory activity in albino rats as well as anti-cancer activity against sarcoma 180 cell line in mice.\[[@ref9]\] Both compounds showed remarkable inhibitory effect on mouse spontaneous mammary tumors.\[[@ref10]\] Triterpenes are also known to augment the inhibitory effects of anti-cancer drugs.\[[@ref11]\] Also it has been known to benefit in Alzhiemer\'s and Parkinsonism.\[[@ref12]\] Taraxerol is known to induce apoptosis, COX inhibitor,\[[@ref13]\] acetyl cholinesterase inhibitor,\[[@ref14]\] and possess anti-microbial potential.\[[@ref15]\] Taraxasterol is anti-allergic,\[[@ref16]\] anti-oxidant,\[[@ref17]\] and anti-inflammatory.\[[@ref18]\] Taraxerol is also known to benefit in diabetes.\[[@ref19]\] Both the compounds are also known to exhibit activity against snake venom.\[[@ref20]\] [Table 1](#T1){ref-type="table"}, below, enlists medicinal plants containing taraxerol and taraxasterol.

###### 

List of medicinal plants containing taraxerol and taraxasterol

![](PRev-9-19-g003)

LIMITATIONS AND FUTURE PROSPECTS {#sec1-3}
================================

Although there are many lead compounds with promising potential for cancer therapy, the cytotoxicity would itself become a constraint for this because most of these compounds could be cytotoxic towards normal cells in addition to the cancerous cells. Various researches have been carried out on both these compound\'s anti-cancer activity on animal cell lines but further researches must be carried out to find out the effect of these compounds on human cancer cell lines and specificity of these compounds on cancer cells. Also, the research must be carried out to ascertain the possible mechanism of action of both these compounds as no satisfactory data is available for mechanism of anti-cancer activity of these compounds as well as their adverse effects must be also assessed. Therefore, considerable cytotoxicity studies must be conducted employing the lead compounds before introducing them to drug development phase. However, advances in drug delivery systems could be applied effectively in specific delivery of therapeutics. Cancer cells carry specific receptors that are expressed at higher levels than their normal counterparts. Often these receptors have binding affinity towards specific proteins or peptides and these can be used for direct targeting of cancer cells which is effectively applicable to develop targeted delivery systems. Nano drug carriers coated with cancer cell receptor binding factors are novel and effective approach for the targeted delivery of drugs. This method can be used to deliver anti-cancer triterpenols to the cancer tissues and thereby protecting the normal adjacent tissue cells.\[[@ref48]\] Moreover, the possibility of continous supply of the product and the ecological importance of the triterpene sources are factors of importance before entering the drug development phase. Sustainable production of these compounds through chemical synthesis or isolation must be ensured. The structural complexities have challenged the chemical synthesis and thus it would be a limitation to the entering of these compounds to the drug development phase. However, with the advances in synthetic chemistry and an understanding of the biosynthetic pathway of triterpenes newer opportunities for exploitation of these compounds as drug leads are opening up.\[[@ref49]\]

CONCLUSION {#sec1-4}
==========

Plant tissue culture science has recently reported various elite gemplasms which constitutes high amount of therapeutically active compounds then its native form. Lower native concentration of taraxerol and taraxasterol limits its applications in pharmaceutical science. Tissue culture science has successfully explored various germplasms to manipulate the *in vitro* conditions for elevating the concentration of these compounds in their native form. Anticancer and other potential properties of these compounds attracted tissue culture science to explore various strategies to trigger their concentration and trace their respective pathways for provoking their utilization in the therapeutic world. Optimization/manipulation of *in vitro* conditions, tracing biosynthetic pathways, elicitation, precursor feeding, immobilization, and genetic manipulation still holds promises in understanding the facts that hinders native synthesis of such biomarker compounds. Nevertheless, of significant challenges remain: Cancer still remains to be a disease of unknown etiology and none of the therapies described represents a cure. It will be interesting to see whether the progress in Indian herbs to generate novel formulation will eventually provide the profound insights required to conquer this condition for the next 25 years.
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